AI Generated Image
Wegovy and Zepbound are changing how Americans get health care
USA Today • • health
Key Points:
- GLP-1 weight-loss drugs like Wegovy and Zepbound are significantly reducing the demand for bariatric surgeries, with a 34% drop in such operations from 2022 to 2024 as GLP-1 use surged 140%, according to a 2026 JAMA study.
- These medications not only aid weight loss but also improve heart health, reducing major cardiovascular events by 20% in overweight or obese adults without diabetes, potentially lowering the need for expensive heart procedures.
- The rise of GLP-1 drugs is shifting healthcare economics from late-stage interventions to proactive obesity management, but access remains uneven as some employers and insurers, including Starbucks, are dropping coverage due to high costs.
- Next-generation weight-loss drugs like Eli Lilly’s retatrutide show promise with weight loss comparable to surgery, contributing to a booming market expected to reach $105 billion globally by 2030.
- Experts warn that reduced insurance coverage for GLP-1 drugs risks reversing health gains for patients, leading to weight regain and resurgence of cardio-metabolic diseases, highlighting the importance of maintaining access to these medications.
